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Thermosensitive Micellar Hydrogels
as Vehicles to Deliver Drugs With
Different Wettability
Rossella Laurano and Monica Boffito*
Department of Mechanical and Aerospace Engineering, Politecnico di Torino, Turin, Italy
The design of adaptable drug delivery systems able to encapsulate and release drugs
with different wettability has been attracting widespread interest. Additionally, many
attempts have been made to tune hydrophobic/hydrophilic drug release kinetics over
time, avoiding the so-called burst release. In this scenario, hydrogels resulting from
the assembly of micellar structures showing a hydrophobic core and a hydrophilic
shell could represent a promising alternative to design versatile drug vehicles. In
this regard, this work aimed at designing new thermosensitive micellar hydrogels
starting from a custom-made amphiphilic poly(ether urethane) (PEU). Specifically, a
commercial triblock copolymer (Poloxamer R© 407), selected to ensure the temperature-
driven chain arrangement into micelles, was reacted with 1,6-diisocyanatohexane
and 1,4-cyclohexanedimethanol. The successful PEU synthesis was proved by size-
exclusion chromatography (Mw 50000 Da) and infrared spectroscopy. Subsequently, the
wettability-driven drug arrangement within the micelle network as well as the influence of
drug-loading on the resultant formulation thermosensitivity was investigated by selecting
ibuprofen (IBU) and ibuprofen sodium salt (IBUSS) as hydrophobic and hydrophilic
drugs, respectively. Specifically, growing drug amounts were loaded into PEU solutions,
and the average hydrodynamic micelle diameters and the critical micellar temperatures
(CMT) were measured. Systems containing IBU at the highest tested concentration (i.e.,
20 mg/mL) showed a significantly higher micelle average diameter (58.2 ± 4.7 nm)
and a remarkably lower CMT (8.9◦C) with respect to both the control (40.1 ± 1.4 nm
and 21.6◦C) and IBUSS-loaded formulations (37.3 ± 2.1 nm and 22.4◦C). Then,
the influence of drug encapsulation on the temperature at which micelles begin to
aggregate was rheologically assessed, showing that IBU-loading induced a decrease
in this parameter (14.6, 8.7, and 13.7◦C for virgin, IBU-loaded, and IBUSS-loaded
hydrogel, respectively). Finally, IBU and IBUSS releasing mechanism was analysed using
the Korsmayer–Peppas model (n value of 0.63 ± 0.007 and 0.89 ± 0.003 for IBU-
and IBUSS-loaded gels, respectively). Thanks to their micellar organisation, the here-
developed hydrogel platform allowed the encapsulation of a high number of molecules
with different wettability. Additionally, these systems exhibited tunable payload-releasing
time without burst release and open the way toward the engineering of smart systems
for the sustained co-delivery of multiple drugs in a target tissue/organ.
Keywords: polyurethanes, hydrogels, smart vehicles, thermo-sensitivity, drug delivery systems, micellar gels,
drug wettability, tunable release
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INTRODUCTION
During the last years, the design of smart drug delivery systems
has emerged as an ambitious challenge due to the need to
(i) deliver drugs over time while reducing the administered
dosage, (ii) reduce side effects associated to non-target tissues,
and (iii) increase drug therapeutic efficacy in the pathological
site. In this scenario, thermosensitive hydrogels are promising
candidates as drug vehicles due to their ability to encapsulate
therapeutic agents in the sol state, undergo a temperature-driven
sol-to-gel transition entrapping drug molecules, and release their
payload upon in situ injection (Gong et al., 2013; Dimatteo
et al., 2018; Ghasemiyeh and Mohammadi-Samani, 2019). In
addition, thermosensitive gels do not show cytotoxic effects
associated with their gelation process, as they do not require
neither chemical crosslinking agents nor potentially dangerous
crosslinking reactions (e.g., photo-curing with UV light, in
particular within the UVB and UVC range) to undergo gelation.
However, two challenging issues are still attracting the attention
of the research community working on this topic: (i) payload
burst release upon hydrogel application and (ii) the difficulty in
loading high amounts of hydrophobic drugs within hydrophilic
networks (Hoare and Kohane, 2008; Larrañeta et al., 2018). With
the aim to limit the burst release phenomenon, drug molecules
have been bound to polymeric chains through covalent or non-
covalent interactions. For instance, Andrade-Vivero et al. (2006)
exploited the presence of the amino groups on 4-vinylpyridine or
on N-(3-aminopropyl)methacrylamide monomers incorporated
in poly(hydroxyethyl methacrylate) hydrogels to improve both
the loading efficiency and the release kinetics of ibuprofen and
diclofenac through electrostatic interactions occurring between
the cationic functional groups of the polymer and the anionic
drug molecules. In another work, Nuttelman et al. (2006)
were able to tune dexamethasone release kinetics by covalently
binding drug molecules to mono-acrylated poly(ethylene glycol)
(PEG) chains, later incorporated into PEG-based hydrogels
through photopolymerisation. Alternatively, the control over
drug release can be carried out by tuning the crosslinking
degree of interpenetrating polymer networks (IPNs) (Li et al.,
2007), reducing the permeability of the external hydrogel surface
(Matsusaki et al., 2007), or designing systems with an additional
diffusive barrier for drugs (e.g., hydrogels containing drug-
loaded particles). In this regard, Boffito et al. (2019b) recently
reported a significant reduction of the initial drug burst release
of approximately 85% through the design of hybrid sol-gel
systems composed by an injectable thermosensitive hydrogel
and ibuprofen-loaded mesoporous silica matrices. A similar
approach was also reported by Chen et al. (2004), who designed
injectable Poloxamer R©-based hydrogels containing lidocaine-
loaded microspheres. On the other hand, the approaches reported
in literature to improve the loading efficiency of hydrophobic
drugs usually consist of the introduction of hydrophobic
domains within the hydrogel network or the addition to
the gel solution of specific molecules (e.g., cyclodextrins) as
drug reservoir. For example, Liu et al. (2007) reported an
improvement in the loading efficiency and a reduction in
diffusion-release rate of p-hydroxyanisole from hydrophobically
modified poly(methacrylic acid) hydrogels. In another work,
Zhang et al. (2005) were able to improve the release rate of
hydrophobic drugs through their incorporation in acryolyl-β-
cyclodextrins, later co-polymerised with N-isopropylacryl amide.
However, in all the aforementioned studies the addition of
specific polymeric segments to the hydrogel solution or further
processing steps during hydrogel preparation were required
to minimise drug burst release and/or to increase drug-
loading efficiency.
In this scenario, the design of micellar hydrogels could
simultaneously face both the previously discussed issues.
Indeed, the presence of both hydrophilic and hydrophobic
segments in the amphiphilic polymer chains allows the
formation of micellar structures with a hydrophobic core
and a hydrophilic shell upon temperature increase. As a
consequence, this micellar organisation allows good interaction
with both hydrophilic and hydrophobic drugs and a prolonged
payload release over time. Among the different compositions
of amphiphilic polymers reported in literature, poly(ethylene
oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-
PEO) triblock copolymers are the most widely investigated for
drug delivery applications (Bodratti and Alexandridis, 2018;
Rey-Rico and Cucchiarini, 2018). These materials are FDA
approved, commercially available (trademarks Poloxamer R© or
Pluronic R©) in a variety of different compositions (i.e., molecular
weight and PEO content), and highly cytocompatible with no
irritation after topical or parenteral administration. However,
hydrogels based on Poloxamers R© usually suffer from poor
residence time in aqueous environments (Boffito et al., 2016),
negatively affecting drug release kinetics and leading to burst
release. With the aim to overcome these drawbacks, in 2016 we
reported the synthesis of a Poloxamer R© 407-based poly(ether
urethane) which aqueous solutions exhibited faster gelation,
higher mechanical performances, and improved stability in
aqueous environment compared to thermosensitive hydrogels
based on native Poloxamer R© 407 as such (Boffito et al., 2016).
The capability of Poloxamer 407-based PEU gels to progressively
release both hydrophilic and hydrophobic molecules as well
as ionic species has been already reported (Boffito et al.,
2019a,b). However, the literature lacks a thorough investigation
of the interactions occurring between drugs and micellar
structures. Thus, starting from the high promise of PEU-
based hydrogels as drug delivery systems, in this work we
characterised the interactions occurring between polyurethane
micelles and drugs with different wettability at both the nano-
and macro-scales. Furthermore, the effects of drug wettability
on hydrogel thermosensitive behaviour and on drug release
time were also studied. To this aim, a thermosensitive micellar
hydrogel was designed starting from the synthesis of a custom-
made amphiphilic poly(ether urethane) (PEU). Specifically, a
poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide)
triblock copolymer (Poloxamer 407) was selected as macrodiol
to ensure polymer thermosensitivity, while 1,6-hexamethylene
diisocyanate and 1,4-cyclohexanedimethanol were identified as
diisocyanate and chain extender, respectively, to obtain a high
molecular weight PEU (Pontremoli et al., 2018). Subsequently,
drugs with different wettability (ibuprofen and ibuprofen sodium
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salt as hydrophobic and hydrophilic drug, respectively) were first
loaded in PEU solutions at different concentrations. Then, their
interactions with the temperature-induced micelle formation and
nucleation processes was studied through the measurement of
the average hydrodynamic micelle diameters and the estimation
of the critical micellar temperature (CMT). In addition, both
drug-loaded and not-loaded hydrogels were qualitatively and
quantitatively characterised through tube inverting and gelation
time tests and rheological analyses, respectively, to investigate
the effect of drug encapsulation on hydrogel thermosensitivity
and gelation process. Lastly, the drug release mechanism from
gels embedding ibuprofen or ibuprofen sodium salt was assessed
by means of drug release tests and the estimation of the release
exponent values that characterise the drug transport mechanism
according to the Korsmeyer–Peppas model.
MATERIALS AND METHODS
Materials
Poloxamer 407 [P407, poly(ethylene oxide)-poly(propylene
oxide)-poly(ethylene oxide) triblock copolymer, Mn 12600 Da,
70% w/w poly(ethylene oxide)], 1,4-cyclohexanedimethanol
(CDM), 1,6-hexamethylene diisocyanate (HDI), and dibutyltin
dilaurate were purchased from Sigma-Aldrich, Italy. Before use,
reagents were treated according to the protocol proposed by
Pontremoli et al. (2018) to remove residual water. Briefly, P407
was dried under reduced pressure (approximately 200 mbar)
at 100◦C for 8 h and then cooled down at room temperature
under vacuum; HDI was distilled under reduced pressure; CDM
was stored at room temperature (RT) in a desiccator; 1,2-
dichloroethane (DCE) was poured over activated molecular
sieves (3 Å, Sigma Aldrich, Italy) and maintained overnight under
nitrogen atmosphere. All solvents were purchased from Carlo
Erba Reagents (Italy) in analytical grade.
Methods
Synthesis of Amphiphilic P407-Based Poly(Ether
Urethane)
The P407-based poly(ether urethane) used in this work was
synthesised following the pre-polymerisation method recently
described by Laurano et al. (2019) (Supplementary Figure S1).
Specifically, P407 was first dissolved in DCE (20% w/V
concentration) at 80◦C under continuous nitrogen flow. Then,
HDI was added at 2:1 molar ratio with respect to P407 and
the pre-polymerisation reaction proceeded for 150 min after
the addition of a catalytic amount of dibutyltin dilaurate (0.1%
w/w). Subsequently, the mixture was cooled down at 60◦C and
CDM (3% w/V in DCE) was added to the isocyanate-terminated
prepolymer solution at 1:1 molar ratio with respect to P407. This
second step of the reaction was carried on for 90 min and finally
terminated through the addition of anhydrous methanol. The
polymer was finally collected by precipitation in petroleum ether
(4:1 volume ratio with respect to DCE total volume). To remove
the catalyst and residual by-products, the polymer was then
dissolved in DCE (20% w/V) and purified through precipitation
in a mixture of diethyl ether/methanol (98/2 V/V, 5:1 volume
ratio with respect to DCE). Finally, PEU was collected through
centrifugation (Hettik, MIKRO 220R) at 0◦C and 6,000 rpm for
20 min, dried overnight under the fume hood, and stored at 4◦C
under nitrogen atmosphere until use.
Hereafter, the synthesised PEU will be named CHP407, where
C, H, and P407 identify the chain extender, the diisocyanate and
the macrodiol, respectively.
Attenuated Total Reflectance Fourier Transform
Infrared Spectroscopy
Attenuated Total Reflectance Fourier Transform Infrared (ATR-
FTIR) spectroscopy was conducted on CHP407 samples to verify
the success of the synthesis. Analyses were performed at RT using
a Perkin Elmer spectrum 100 equipped with an ATR accessory
(UATR KRSS) with diamond crystal. Spectra resulted from 32
scans in the range of 4,000 to 600 cm−1 with a resolution
of 4 cm−1. Analyses were elaborated using the Perkin Elmer
software and results are reported as average spectra of three
different polymer batches.
Size Exclusion Chromatography
Size Exclusion Chromatography (SEC) analyses were performed
through an Agilent Technologies 1200 Series (CA, United States)
to estimate the molecular weight of the synthesised PEU. The
instrument was equipped with a Refractive Index (RI) detector
and two Waters Styragel columns (HR1 and HR4) conditioned at
55◦C. N,N-dimethylformammide (DMF, CHROMASOLV Plus,
inhibitor free, for HPLC, 99.9%, Carlo Erba Reagents, Italy),
added with 0.1% w/V LiBr (Sigma Aldrich, Italy), was used
as mobile phase. A calibration curve based on poly(ethylene
glycol) standards was defined in the range of peak molecular
weight Mp 4,000 – 200,000 Da. Before analyses, 2 mg of polymer
were dissolved in 1 mL of mobile phase and filtered through
a 0.45 µm syringe filter [poly(tetrafluoroethylene) membrane,
Whatman]. Number Average Molecular Weight (Mn), Weight
Average Molecular Weight (Mw) and dispersity index (D) were
estimated using the Agilent ChemStation software.
Dynamic Light Scattering
To thoroughly investigate the relationship occurring between
drug loading and changes in micelle hydrodynamic diameter,
dynamic light scattering (DLS) measurements were performed
on CHP407 samples loaded or not-loaded with drugs
characterised by a different wettability. Specifically, CHP407 was
first dissolved at 0.5% w/V in physiological saline solution (0.9%
NaCl); then Ibuprofen (IBU, Sigma Aldrich, Italy) or Ibuprofen
Sodium Salt (IBUSS, Sigma Aldrich, Italy), as hydrophobic or
hydrophilic drug, respectively, was added to PEU solution at 2,
5, 10, or 20 mg/mL concentration. Analyses were performed at
25, 30, and 37◦C, according to the protocol recently published
by Laurano et al. (2020), using a Zetasizer Nano S90 (Malvern
Instruments, Worcestershire, United Kingdom) instrument.
Before starting, samples were equilibrated at the test temperature
for 15 min and then analysed according to Pradal et al. (2013).
The reported hydrodynamic diameters resulted from the
average of three different analysed samples. Data are reported as
mean± standard deviation.
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Hereafter, drug loaded-CHP407 aqueous solutions (0.5%
w/V) will be referred to as CHP407_IBU_Xmg/mL and
CHP407_IBUSS_Xmg/mL, where X stands for the amount of
encapsulated drug.
Critical Micellar Temperature
To investigate the effect of drug loading on the temperature
at which micelle nucleation begins, the CMT of CHP407-
based aqueous solutions was estimated using a fluorescent
dye (1,6-diphenyl-1,3,5-hexatriene, DPH, Sigma Aldrich, Italy)
as micellization marker. Samples (1 mL) were prepared
by dissolving the polymer at 0.5% w/V concentration in
physiological saline solution. Regarding the preparation of drug-
loaded systems, IBU and IBUSS were first solubilised in ethanol
and double-distilled water, respectively, at 40 mg/mL and then
added to CHP407 solution (previously dissolved at slightly higher
concentration) in order to reach the final volume of 1 mL and
different drug concentrations (i.e., 2, 5, 10, and 20 mg/mL).
Lastly, DPH (previously dissolved in methanol at 0.4 mM) was
added to each sample at 10 µL/mL. Analyses were conducted
according to the method described by Alexandridis et al. (1994).
Briefly, virgin and drug-loaded solutions were heated between 5
and 40◦C at 1◦C/step, each step consisting of 5 min equilibration
followed by UV/Vis spectra recording in the 500 nm to 300 nm
spectral range (PerkinElmer, Lambda 25). Then, for each sample,
the recorded absorbance values at 356 nm were plotted as
a function of temperature obtaining a sigmoidal curve. The
CMT was defined as the temperature corresponding to the first
inflexion of this sigmoidal curve.
Hereafter, samples will be referred to as defined in the section
“Dynamic Light Scattering.”
Preparation of Drug-Loaded Hydrogels
Virgin CHP407 hydrogels were prepared by dissolving the
polymer at 15% w/V concentration in physiological saline
solution overnight at 4◦C according to the protocol published by
Pontremoli et al. (2018). In order to prepare drug-loaded gels, an
aliquot of IBU or IBUSS solution previously prepared in EtOH
or double-distilled water respectively (40 mg/mL) was first added
to physiological solution to reach a final drug concentration of
1 mg/mL and then, the resulting medium was used to solubilise
CHP407 at 15% w/V concentration (Supplementary Figure S2).
Hereafter, IBU- and IBUSS-loaded gels will be referred to as
CHP407_IBU and CHP407_IBUSS.
Tube Inverting Test
To qualitatively investigate the effect of drug encapsulation on
hydrogel thermo-sensitivity, Tube Inverting Test was performed
on all the formulated CHP407-based hydrogels. Specifically,
samples were first prepared in bijou sample containers with
an inner diameter of 17 mm (CarloErba reagents, Italy) as
previously described (see paragraph “Preparation of drug-
loaded hydrogels”); then, they were subjected to a controlled
temperature increase from 4 to 40◦C at 1 ± 0.1◦C/step and
5 min equilibration time. At each step, samples were inverted to
allow the visual inspection of the sol-to-gel transition. Sol and gel
conditions were defined as “flow liquid sol” and “no flow solid
gel,” respectively, within 30 s of observation. In order to better
evaluate result variability due to operator’s perception of both sol
and gel states, the test was performed by three different operators,
each of them characterising a set of all formulated compositions.
Results are reported as mean± standard deviation.
Gelation Time at Physiological Temperature
Gelation time test at physiological temperature (i.e., 37◦C) was
performed to qualitatively evaluate the time required by loaded-
and not-loaded hydrogels to undergo a sol-to-gel transition.
Samples were prepared as previously described (see paragraph
“Preparation of drug-loaded hydrogels”) and incubated at
37◦C (Memmert IF75). At predefined time points (1–10 min,
1 min/step), hydrogels were inverted for 30 s to allow the visual
inspection of the sol and gel states (defined as in the Tube
Inverting Test). At the end of each step, samples were kept in
an ice bath for 8 min to ensure that all the systems were in
the sol state prior to the following incubation at 37◦C. Result
variability deriving from the qualitative evaluation of sol and gel
conditions was investigated by asking to three different operators
to characterise three different sets of formulations. Results are
reported as mean± standard deviation.
Rheological Characterisation
To thoroughly investigate hydrogel gelation mechanism and
kinetics in the presence of hydrophobic or hydrophilic drugs,
CHP407_IBU and CHP407_IBUSS were characterised using
a stress-controlled rheometer (MCR302, Anton Paar Gmbh,
Graz, Austria). The instrument was equipped with a 50 mm
parallel plate geometry and a Peltier system for temperature
control. CHP407 hydrogels were also analysed as control
condition. Sol-to-gel transition was studied through temperature
ramp tests carried out in the range 0◦C–40◦C, 2◦C/min,
0.1 s−1 frequency. On the other hand, strain sweep tests
were conducted at 37◦C (10 Hz, strain range 0.01–500%)
to investigate gel resistance to applied deformation. Lastly,
frequency sweep tests were performed within the linear
viscoelastic region (frequency range 0.1–100 rad/s, strain
0.1%) at 25, 30, and 37◦C to characterise gel viscoelastic
properties. For each analysis the sample was poured on
the lower plate in the sol state at 0◦C, heated at the test
temperature and equilibrated for 10 min to reach thermal stability
and finally tested.
Drug Release
The relationship between drug wettability and their release
mechanism and timing from micellar hydrogels was studied
through drug release tests conducted up to 14 days at 37◦C.
Specifically, drug-loaded hydrogels (1 mL) were prepared as
previously described in paragraph “Preparation of Drug-Loaded
Hydrogels” and incubated at 37◦C for 15 min to ensure a
complete sol-to-gel transition. Subsequently, 1 mL of Trizma R©
(0.1 M, pH 7.4, Sigma Aldrich, Italy) previously equilibrated at
the test temperature was added to each sample as release medium.
Extracts were collected and completely refreshed at different time
points (i.e., 15, 30, 45, 60, 90 min, 2, 3, 4, 5, 7 h, 1, 2, 5, 7,
and 14 days). Released drugs were then quantified according to
the method proposed by Alsirawan et al. (2013) using a High-
Performance Liquid Chromatography (HPLC, Thermo Scientific,
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Dionex Ultimate 3000) instrument equipped with a C18 column
(5 µm, 120 Å). Acetonitrile (ACN, CarloErba Reagents, Italy,
HPLC grade) and phosphoric acid solution at 0.03% w/V were
mixed at 60/40 V/V and used as mobile phase by setting
1.7 mL/min as flow rate. According to the selected mobile phase,
400 µL of each extract were added to 600 µL of ACN, to
obtain a final Trizma R©/ACN volume ratio of 40/60. Samples were
then filtered through a 0.45 µm syringe filter [Macherey-Nagel,
poly(tetrafluoro ethylene) membrane] and analyses were carried
out at RT and 214 nm for 5 min with an injection volume
of 20 µL. Subsequently, drugs were quantified by referring to
a calibration curve based on IBU or IBUSS standards with
concentration in the range of 0–1 mg/mL. Lastly, to better
understand whether different release mechanisms occurred in the
presence of IBU or IBUSS, the Korsmeyer–Peppas model was
applied to the release data and the drug transport mechanism
was defined based on the estimated release exponent n value
(Dash et al., 2010).
Statistical Analysis
Statistical analysis was performed using GraphPad Prism 8.0 for
MacOsX (GraphPad Software, La Jolla, CA, United States1).
Two-way ANOVA analysis followed by Bonferroni’s
multiple comparison test was used to compare results. The
statistical significance of each comparison was assessed as




ATR-FTIR spectroscopy performed on both the macrodiol
and the synthesised polyurethane reported the appearance of
new bands in CHP407 spectrum if compared to P407 one
(Supplementary Figure S3). In detail, the peak at 1,720 cm−1
and 1,630 cm−1 can be ascribed to the stretching vibration of
carbonyl groups; the band at 3,350 cm−1 can be attributed to
the stretching vibration of N-H bonds, while at 1540 cm−1 the
spectrum showed the bending vibration of N-H bonds together
with the stretching vibration of C-N bonds. In addition, CHP407
showed an increased Mn compared to P407 (30,000 Da versus
10,000 Da) further confirming the success of the synthesis and
a dispersity index of 1.6.
Investigation of the Interactions
Occurring Between PEU Micelles and
Drugs With Different Wettability
Measurement of Micelle Average Hydrodynamic
Diameter
To investigate the effect of drug loading on micelle nucleation
and on their corresponding hydrodynamic diameter, DLS
measurements were conducted at three different temperatures
on samples loaded with different amounts of IBU or IBUSS.
1www.graphpad.com
Virgin CHP407 solutions were also analysed as control condition.
Specifically, Figure 1 reports DLS volume patterns of systems
encapsulating the drugs at 2 and 20 mg/mL concentration,
while results concerning CHP407 solutions loaded with IBU
or IBUSS at 5 and 10 mg/mL concentration are illustrated in
Supplementary Figure S4.
As reported in Figure 1 (left column), irrespective of the
analysed temperature, no differences were observed between
CHP407 and drug-encapsulating CHP407 profiles when systems
were loaded at a low IBU or IBUSS concentration (i.e.,
2 mg/mL). Upon an increase in drug content up to 5 mg/mL
(see Supplementary Figure S4 – left column) an evident shift
toward higher hydrodynamic diameter values was registered
for samples containing IBU (red line) at 37◦C, while no
differences were observed at lower temperatures (i.e., 25 and
30◦C) when compared to the control (blue line) and IBUSS-
loaded CHP407 (green line) profiles. On the other hand,
at the same payload concentration, IBUSS-loaded systems
reported similar profiles with respect to the control at each
analysed temperature. By further increasing drug concentration
at 10 mg/mL and 20 mg/mL (see Supplementary Figure S4
and Figure 1 right columns, respectively), CHP407 solutions
encapsulating IBU reported significant shifts toward higher
hydrodynamic diameters at each tested temperature, thus
suggesting that the introduction of a high amount of a
hydrophobic drug favours the nucleation of bigger micelles.
Conversely, no significant differences were observed between
CHP407 and IBUSS-loaded CHP407 solutions irrespective of
drug concentration and temperature.
Figure 2 reports micelle average hydrodynamic diameter
measured at 25, 30, and 37◦C upon an increase in drug content
from 2 mg/mL up to 20 mg/mL. As expected, no differences
were observed between the analysed systems when IBU and
IBUSS were loaded at 2 mg/mL, with an average diameter
around approximately 30, 35, and 40 nm at 25, 30, and
37◦C, respectively. On the other hand, despite results observed
in the volume patterns at 37◦C for CHP407_IBU_5mg/mL
(see Supplementary Figure S4C), micelles turned out to
show similar average dimensions to those of CHP407 and
CHP407_IBUSS_5mg/mL. Indeed, the average hydrodynamic
diameters were measured to be 39.1 ± 1.4 nm, 37.2 ± 1.8 nm,
and 35.4 ± 1.3 nm for CHP407, CHP407_IBU_5mg/mL,
and CHP407_IBUSS_5mg/mL, respectively. Conversely, slight
differences were observed at 25◦C (35 ± 1.4 nm versus
28.7 ± 4 nm and 28.8 ± 1.2 nm for CHP407_IBU_5mg/mL,
CHP407, and CHP407_IBUSS_5 mg/mL, respectively), thus
suggesting that the addition of a hydrophobic drug favours the
organisation of bigger structures at lower temperatures. Similar
trends were also registered when drugs were encapsulated at
10 mg/mL, with an average hydrodynamic diameter slightly
higher only for CHP407_IBU_10mg/mL at 25◦C. Lastly, at
the highest tested drug concentration (i.e., 20 mg/mL), the
average hydrodynamic diameters of systems loaded with IBU
turned out to be significantly higher compared to CHP407
and IBUSS-containing CHP407 solutions at each analysed
temperature (e.g., average hydrodynamic diameters at 37◦C
were measured to be 40.1 ± 1.4 nm, 58.2 ± 4.7 nm, and
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FIGURE 1 | Distribution patterns (by volume) of micelle hydrodynamic diameter measured in CHP407 solutions at 0.5% w/V concentration not loaded- (blue line) or
loaded with 2 (dashed line) and 20 (continuous line) mg/mL of IBU (red line) or IBUSS (green line). Analyses were performed at 25◦C (A,D), 30◦C (B,E), and 37◦C
(C,F).
FIGURE 2 | Average hydrodynamic diameters of micelles formed in CHP407 (blue), IBU- (red) and IBUSS-loaded (green) solutions (at 2, 5, 10, and 20 mg/mL drug
concentration) at different temperatures (25, 30, and 37◦C) (*p < 0.05, **p < 0.005).
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37.3 ± 2.1 nm for CHP407, CHP407_IBU_20mg/mL, and
CHP407_IBUSS_20mg/mL, respectively).
Estimation of the Critical Micellar Temperature
The CMT was estimated for all considered formulations to
investigate whether the presence of hydrophilic or hydrophobic
drugs could affect the temperature at which micelles begin to
nucleate. Figure 3 reports the UV/Vis spectra recorded for
CHP407-based solutions at 0.5% w/V concentration loaded or
not loaded with IBU or IBUSS at 5 mg/mL (Figures 3B,C) and
20 mg/mL (Figures 3D,E) recorded at different temperatures
(i.e., 15, 20, 25, and 30◦C). Data concerning systems loaded
with drugs at 2 and 10 mg/mL concentration are reported in
Supplementary Figure S5.
At low drug concentration, i.e., 2 mg/mL, no differences
were observed between CHP407_IBU_2mg/mL and
CHP407_IBUSS_2mg/mL as the temperature at which the
intensity of the peak at 356 nm begins to increase turned out to
be 20◦C for both analysed systems (see Supplementary Figures
S5B,C). In addition, this result was in accordance with that of
CHP407 control solution, thus suggesting that the introduction
of a low amount of drug did not affect micelle nucleation
mechanism, irrespective of its wettability.
Upon an increase in drug loading at 5 mg/mL concentration
(Figures 3B,C), slight differences appeared in IBU-loaded
samples as the intensity of DPH signal at 356 nm turned
out to increase at a lower temperature with respect to the
control and CHP407_IBUSS_5mg/mL (i.e., 15◦C versus 20◦C).
By further increasing drug concentration up to 10 mg/mL
and 20 mg/mL, spectra of IBU-containing samples (see
Supplementary Figure S5D and Figure 3D, respectively) were
almost overlapped at each reported temperature. This evidence
suggested that DPH solubilisation into the micelle core began
at a very low temperature and that at 10◦C its complete
encapsulation was almost achieved. On the other hand, CHP407
samples loaded with IBUSS (see Supplementary Figure S5E and
Figure 3E) showed similar trends to those reported for lower
drug concentrations.
Lastly, CMT values were estimated for all considered systems
(see Supplementary Figures S6, S7) according to Boffito et al.
(2016) and reported in Table 1. As expected, similar CMT
values were observed for CHP407-based solutions not loaded or
loaded with 2 mg/mL of IBU or IBUSS. However, upon drug
content increase at 5, 10, or 20 mg/mL, the presence of IBU
sharply lowered the CMT value of the system (i.e., CMT = 8.9◦C
for CHP407_IBU_20mg/mL), thus indicating that hydrophobic
molecules enhanced micelle nucleation at lower temperatures.
Conversely, irrespective of drug concentration, the introduction
of IBUSS did not affect the process, with respect to the control.
Effect of Payload Encapsulation on
Hydrogel Thermosensitivity
Tube Inverting and Gelation Time Tests
To qualitatively evaluate the influence of drug encapsulation
on hydrogel thermo-sensitivity, tube inverting test and gelation
time test at physiological temperature were performed on virgin
hydrogels at 15% w/V concentration and on systems loaded with
1 mg/mL concentration of drug. Results are reported in Figure 4.
Regarding tube inverting test, drug loading seemed to slightly
affect the gelation temperature of the hybrid systems irrespective
of drug wettability. Indeed, gelation temperatures turned out to
be 29.7± 0.6◦C, 27.3± 0.6◦C, and 28.0± 1◦C for virgin CHP407,
CHP407_IBU, and CHP407_IBUSS hydrogels, respectively. On
the other hand, almost no differences were registered in their sol-
to-gel transition time at 37◦C.
Rheological Characterisation
In order to thoroughly understand the effect of drug encapsu-
lation on sol-to-gel transition upon temperature increase, a
complete rheological characterisation was performed on virgin
CHP407 hydrogels and on systems loaded with IBU or IBUSS.
Figure 5 illustrates changes in solution viscosity recorded upon a
controlled temperature ramp increase in the range 0–40◦C.
In all analysed systems, viscosity initially decreased as a
function of temperature according to the characteristic behaviour
of sol systems subjected to a heating process. Then, a sharp
viscosity increase was observed as a consequence of chain
arrangement into an organised structure until complete sol-to-
gel transition. In terms of trend of viscosity versus temperature,
marked differences were observed among the investigated
formulations, as the viscosity of CHP407_IBU (red line) started
to increase at a lower temperature compared to the control and
CHP407_IBUSS. Finally, the viscosity suddenly fell down at high
temperatures (i.e., 35–36◦C) due to gel melt fracture (Boffito
et al., 2016), with no differences among the tested samples. The
temperature at which the viscosity reaches the lowest value is
defined as Tonset . This temperature is a crucial gelation parameter
as it marks the beginning of the micelle nucleation process. The
Tonset values estimated for the analysed systems are reported
in Table 2.
The addition of IBUSS to CHP407 solutions did not
significantly affect either the system minimum viscosity value or
the Tonset , which was measured to be 14.6 and 13.7◦C for CHP407
and CHP407_IBUSS, respectively. Concerning CHP407_IBU,
consistent differences were registered with respect to the
control in Tonset value, thus suggesting that the introduction of
hydrophobic molecules could affect gelation mechanism.
Strain sweep tests conducted at 37◦C (Supplementary
Figure S8) measured storage and loss moduli (G’ and G”,
respectively) values as a function of applied deformation. While
similar storage and loss moduli values (approximately 7 and
1.6 kPa for G’ and G”, respectively) were registered within the
linear viscoelastic region (i.e., strain range in which G’ and G” are
constant) for both unloaded- and drug-loaded gels, a significantly
lower strain resistance was observed for CHP407_IBU (11.6%
versus 18.6% strain at break for IBU-loaded and virgin/IBUSS-
loaded gels, respectively), thus suggesting a different micelle
organisation within the network in the presence of IBU.
Lastly, frequency sweep tests at 25, 30, and 37◦C allowed the
investigation of hydrogel gelation kinetics through the variation
of G’ and G” upon temperature increase (Figure 6). In general,
G’ values lower than G” ones characterise a system in the sol
phase; conversely, G’ values higher than G” ones are indicative
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FIGURE 3 | UV/Vis spectra of virgin CHP407 solution (0.5% w/V concentration) (A) and IBU- and IBUSS-loaded formulations (red and green line, respectively) at
5 mg/mL (B,C) and 20 mg/mL (D,E) upon temperature increase in the range 5–40◦C.
of a gel behaviour. The frequency at which G’ becomes higher
than G”, i.e., the crossover frequency (ωG ′/G ′′ crossover), marks the
transition from the typical behaviour of a sol toward that of
a gel. Those samples that exhibit a G’/G” crossover within the
investigated frequency range are defined as biphasic systems. The
analysed systems turned out to be almost completely in the sol
state at 25◦C, in a biphasic phase at 30◦C, and almost completely
in the gel state at 37◦C, although a complete gel development
was not achieved because G’ and G” were not frequency-
independent. However, the crossover frequency values reported
in Table 3 suggested different gelation kinetics, with respect to
the control sample, in the presence of both hydrophobic and
hydrophilic drugs. Indeed, at 25◦C the crossover frequencies of
CHP407_IBU and CHP407_IBUSS hydrogels (i.e., 50 rad/s and
45 rad/s, respectively) were measured to be at lower frequencies
if compared to CHP407 gels (i.e., 58 rad/s). Upon temperature
increase up to 30◦C, CHP407_IBU and CHP407 reached the
G’/G” crossover at the same angular frequency (i.e., 4 rad/s), while
CHP407_IBUSS exhibited the G’/G” crossover at 2.5 rad/s. Lastly,
at 37◦C all systems showed almost the same ωG ′/G ′′ crossover ,
suggesting that all the formulations achieved the same degree of
network organisation.
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Investigation of Payload Releasing
Mechanism and Kinetics From Micellar
Hydrogels
To study whether drug wettability could influence their release
mechanism from micellar hydrogels, IBU and IBUSS, as
hydrophobic and hydrophilic drug, respectively, were loaded
in CHP407 gels at 1 mg/mL and their release kinetics was
thoroughly investigated (Figure 7).
Irrespective of the nature of the encapsulated drugs, a
sustained release over time was observed from CHP407-based
hydrogels up to 14 days. In addition, starting from 7 h of
incubation, IBUSS release (green line) was significantly higher
than that of IBU (red line) at each analysed time point. However,
considering the initial time steps up to 1 h, a delayed IBUSS
release was registered followed by a sharp increase up to 7 h
and finally by a sustained release which became complete on day
14. On the other hand, IBU-loaded hydrogels initially showed an
increased payload release compared to IBUSS-loaded ones (8.5%
versus 3.7% at 30 min of incubation) followed by a sustained
release up to 14 days (approximately 95% released IBU). Thus,
three and two different curve slopes could be identified in IBUSS
and IBU profiles, respectively, which suggest the occurrence of
different drug release mechanisms, and thus different release
kinetics, as a consequence of drug wettability. In particular, 5 h
incubation time marked a significant change in drug release
kinetics as starting from this time point released IBUSS turned
out to be always higher than IBU.
Lastly, to deeply investigate the mechanism underpinning the
release of IBU or IBUSS within the first hours of incubation, the
Korsmeyer–Peppas model was applied to drug-loaded CHP407
hydrogels (Dash et al., 2010). Specifically, the releasing exponent
n was estimated for both CHP407_IBU and CHP407_IBUSS
systems and they were measured to be 0.63 ± 0.007 and
0.89 ± 0.003, respectively. These results suggest the occurrence
of two different release mechanisms of IBU and IBUSS from
CHP407 gels, according to Dash et al. (2010).
DISCUSSION
Thermosensitive hydrogels are gaining increasing interest as drug
delivery systems due to their capability to load high amounts of
drugs. Moreover, the high water content of hydrogels perfectly
mimics the extracellular matrix structure, thus reducing the
probability of an adverse immune system response. However, the
strong hydrophilic nature of these systems significantly limits
the amount of hydrophobic drugs that can be encapsulated
(Hoare and Kohane, 2008). To overcome this drawback, the
introduction of hydrophobic blocks in the polymeric component
can offer a higher number of binding sites to hydrophobic drugs,
thus increasing the loading yield (Zha et al., 2002). However,
this strategy generally requires a further functionalisation step.
A promising alternative could be represented by micellar
hydrogels, as their polymeric chains are composed by an
alternation of hydrophobic and hydrophilic segments that upon
temperature increase can arrange into organised structures with
TABLE 1 | Estimated critical micellar temperatures for virgin CHP407 solutions at
0.5% w/V concentration and drug-loaded formulations at 2, 5, 10, and
20 mg/mL concentration.







0 mg/mL 21.6 – –
2 mg/mL – 21.8 22.7
5 mg/mL – 19.2 22.5
10 mg/mL – 10.7 22.6
20 mg/mL – 8.9 22.4
a hydrophobic core and a hydrophilic shell enhancing the
interactions with drugs of different wettability.
In this work, the influence of drug nature on the temperature-
driven micelle organisation and nucleation process has been
thoroughly investigated at both the nano- and macro-scale. To
this aim, an amphiphilic P407-based poly(ether urethane) was
first synthesised and the success of its synthesis was assessed by
ATR-FTIR spectroscopy. Indeed, the appearance of vibrational
bands at 1,720 cm−1, 3,350 cm−1, and 1,540 cm−1 can be
ascribed to the newly formed urethane bonds between isocyanate
groups and hydroxyl terminal groups of the macrodiol and the
chain extender in the first and second step of the synthesis,
respectively. Furthermore, the absence of the peak attributed
to unreacted isocyanates (i.e., 2,200 cm−1) suggested that the
reaction was complete and successfully carried out as reported
by Boffito et al. (2016). In addition, the band at 1,630 cm−1
suggested the presence of a small amount of urea bonds as a
consequence of side-reactions occurring during PEU synthesis in
accordance with the work recently published by Laurano et al.
(2020). However, these by-products did not affect the successful
synthesis of a poly(ether urethane) characterised by a high
molecular weight and a narrow molecular weight distribution as
assessed through SEC analyses.
The effects of drug wettability on polymer chain arrangement
and micelle organisation were first investigated at the nanoscale
by analysing two characteristic micelle parameters, the CMT
and the average hydrodynamic micelle diameter. The former
was estimated using a fluorescent dye (Alexandridis et al.,
1994), and the latter by adapting to micelle characterisation a
conventional technique (i.e., DLS analyses) usually applied to
solid spherical systems (e.g., nanoparticles) (Hoo et al., 2008;
Lim et al., 2013). Indeed, the presence of the amphiphilic
P407 building block in polyurethane backbone is responsible
for chain organisation into spherical micellar structures upon
system heating according to results published on similar
PEUs differing for their chain extender (Boffito et al., 2016,
2019a; Laurano et al., 2020). Drug encapsulation into CHP407
solutions affected the average hydrodynamic diameter of the
polymeric structures formed at 25, 30, and 37◦C, with significant
differences that can be correlated to molecule wettability.
Specifically, the addition of the hydrophilic IBUSS did not
alter the measured micelle hydrodynamic diameters irrespective
of temperature and its concentration within the sample, thus
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FIGURE 4 | Results of Tube Inverting test (A) and Gelation Time test at physiological temperature (B) performed on CHP407 (blue), CHP407_IBU (red), and
CHP407_IBUSS (green) hydrogels at 15% w/V concentration and loaded with 1 mg/mL concentration of drugs to evaluate their effect on the sol-to-gel transition
process. Results are reported as mean ± standard deviation of three independent analyses performed by three different operators. Systematic errors of tube
inverting test and gelation time test are ± 0.5◦C and ± 30 s, respectively.
FIGURE 5 | Trend of viscosity as a function of temperature within the range
0–40◦C for virgin CHP407 (blue line) at 15% w/V concentration and for hybrid
systems (CHP407_IBU and CHP407_IBUSS, red and green line, respectively)
loaded with 1 mg/mL concentration of drug.
suggesting that no interactions occurred between IBUSS and
micelle nucleation. Indeed, as a consequence of its hydrophilicity,
IBUSS molecules preferentially interact with water molecules
and/or chain hydrophilic segments. Conversely, IBU loading in
CHP407 systems led to the formation of micelles characterised
by higher hydrodynamic diameters with respect to the control
(i.e., not-loaded CHP407 solutions). The formation of bigger
polymeric structures as a consequence of IBU addition within the
samples supported the hypothesis of the progressive hydrophobic
drug arrangement into the hydrophobic micelle core upon
temperature increase. Additionally, drug wettability also affected
the temperature at which micelles began to aggregate (i.e.,
the CMT). Indeed, CMT is dependent on both polymer
TABLE 2 | Tonset and minimum value of measured viscosity (ηmin) estimated for
virgin and drug-loaded systems prepared at 15% w/V concentration and loaded
with 1 mg/mL concentration of drug.
Gelation parameters




concentration, according to Boffito et al. (2016) and Laurano
et al. (2020), and hydrophobic/hydrophilic balance (Okudan
and Altay, 2019). In this work, being the polymeric content
the same in all the analysed formulations, the progressive
decrease of the estimated CMT values could be ascribed to the
loading of increasing amounts of IBU. Indeed, the addition of
hydrophobic drug molecules resulted in an increased system
hydrophobic content, which led to the formation of stronger
hydrophobic interactions and thus to the beginning of micelle
aggregation phenomena at lower temperatures with respect to
the control. On the other hand, the addition of IBUSS raised
the hydrophilic content of the formulations, leading to a slight
delay in polymeric chain arrangement into organised micelles
with respect to the control. Additionally, this phenomenon was
further worsened by the interactions occurring between drug
molecules and chain hydrophilic blocks, which slightly hindered
micelle formation. Therefore, based on these considerations and
on the expected further decrease in CMT values moving from
not-gelling solutions toward hydrogel formulations, in this work
a new method was applied to prepare drug-loaded gels. Indeed,
differently from the protocol we recently published (Boffito et al.,
2019b), this new approach maximised IBU encapsulation within
the hydrophobic micellar core during polymer solubilisation
followed by its arrangement into micelles.
At the macro-scale the encapsulation of drugs in CHP407-
based hydrogels, irrespective of their wettability, seemed to
slightly interfere with the gelation temperatures as suggested by
the Tube Inverting Test. This observation was further proved
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FIGURE 6 | Trends of storage and loss moduli versus angular frequency within the range 0.1–100 rad/s for CHP407 (blue), CHP407_IBU (red), and CHP407_IBUSS
(green) hydrogels at 25, 30, and 37◦C. The storage (G’) and the loss moduli (G”) are reported as continuous and dashed lines, respectively. For high graph clarity, G’
and G” were shifted along the Y axis with respect to the control by a factor of 100 and 10,000 for CHP407_IBU and CHP407_IBUSS, respectively.
TABLE 3 | Crossover frequencies between storage and loss moduli
(ωG ′ /G ′′ crossover ) measured at 25, 30, and 37◦C for virgin and drug-loaded
CHP407-based hydrogels (drug concentration 1 mg/mL).
ω G ′ /G ′′ crossover (rad/s)
25◦C 30◦C 37◦C
CHP407 58 4 0.15
CHP407_IBU 50 4 0.13
CHP407_IBUSS 45 2.5 0.12
by temperature ramp tests, which revealed a decreased Tonset
for both drug-loaded gels with respect to the CHP407 one.
However, the addition of IBUSS only mildly altered the Tonset of
the system, further supporting our observations at the nanoscale
and definitely proving that hydrophilic drug molecules do
not affect the organisation capability of polymeric chains. On
the other hand, the addition of IBU drastically decreased the
temperature at which micelles begin to aggregate. Indeed, IBU
molecules, being encapsulated into the micelle core, as suggested
by DLS measurements, led to the formation of bigger micelles
reaching the critical micellar volume required to trigger the sol-
to-gel transition at lower temperatures (Boffito et al., 2016).
Additionally, the introduction of hydrophobic molecules into
the system brought to increased hydrophobic interactions. This
hypothesis was further confirmed by the measured strain at
break, which was significantly lower for IBU-loaded gels with
respect to IBUSS-loaded and virgin gels. Therefore, the addition
of a hydrophobic drug moves the beginning of the gelation
transition toward lower temperatures and induces the formation
of less mechanically resistant gels. Concerning gel development
kinetics, both drug-loaded hybrid systems were characterised
by faster transitions with respect to the control. Moreover,
this phenomenon was particularly evident in CHP407_IBUSS
hydrogels. Indeed, although micelle aggregation began at lower
temperatures for IBU-loaded gels with respect to IBUSS-loaded
ones, at 25◦C the hydrogel encapsulating the hydrophilic drug
showed a marked lower crossover frequency. These observations
could be explained considering the different drug arrangement
within the network (Figure 8). Specifically, IBU molecules were
encapsulated into the hydrophobic micelle core, leading to the
formation of bigger micellar structures (Figure 8A), meanwhile
IBUSS molecules were entrapped in the interstitial spaces among
micelles (Figure 8B). IBU organisation into micelle core initially
favoured the gelation process lowering the Tonset , but then micelle
nucleation and aggregation into the gel network turned out to be
slightly hindered by their higher hydrodynamic diameters. On
the other hand, hydrophilic drug arrangement with respect to
the surrounding micelles did not alter Tonset value, but speeded
up the sol-to-gel transition kinetics favouring micelle aggregation
and packing into an organised network. However, at 37◦C these
differences between the analysed systems were levelled off as
suggested by gelation time test results, ωG ′/G ′′ crossover values, and
temperature ramp test data. Indeed, although changes in the
onset of gelation were observed, at temperatures higher than
30◦C all the formulations tended to the same viscosity values.
Thus, the here-developed micellar poly(ether urethane)-based
hydrogels pave the way to the design of a drug delivery system
able to encapsulate both hydrophilic and hydrophobic drugs
without significantly altering the resultant hydrogel thermo-
responsiveness.
In addition, the different wettability-driven drug arrangement
into the gel network also affected their release kinetics from
CHP407-based hydrogels. Specifically, the released amount of
IBU turned out to be always lower than that of IBUSS from 7 h
up to 14 days of incubation. Indeed, being encapsulated in the
micelle core, drug molecules had a double diffusive barrier to
pass through before reaching the external medium. However, this
observation was not complied within the first 4 h of incubation
as a consequence of the strong physical interactions occurring
between IBUSS molecules and hydrophilic chain blocks, which
led to a delayed release of the hydrophilic drug compared to
the hydrophobic one (Hoare and Kohane, 2008). This different
releasing mechanism of IBU and IBUSS from CHP407 gels
was also supported by the estimated release exponent n. The
Korsmeyer–Peppas model applied to CHP407_IBUSS gel release
data within the first 7 h of incubation (being this model valid
up to 60% release) evidenced an n value characteristic of case
II transport. Indeed, IBUSS release was determined not only by
diffusion and swelling/relaxation phenomena, but also by the
occurrence of other processes influencing drug release, such as
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FIGURE 7 | Drug release profile of IBU (red line) and IBUSS (green line) loaded at 1 mg/mL in 15% w/V concentrated CHP407 hydrogels. The insert magnifies drug
release profiles within the first 7 h of incubation.
FIGURE 8 | Schematic representation of wettability-driven drug arrangement during chain organisation into micelles upon temperature increase: hydrophobic drugs
loaded inside the micelle core (A) and hydrophilic drug entrapped in the interstitial spaces among micelles (B).
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the electrostatic interactions occurring between IBUSS molecules
and the polymeric chains (Dash et al., 2010; Boffito et al., 2019b).
On the other hand, the Korsmeyer–Peppas model applied to
CHP407_IBU systems gave an n value characteristic of non-
Fickian transport (Dash et al., 2010; Boffito et al., 2019b). Indeed,
the drug first diffused from the micelles within the hydrogel
interstitial spaces and then from the gel in the surrounding
medium. This result is in contrast with our recently published
work (Boffito et al., 2019b), in which we characterised IBU release
as a purely diffusive process. However, this contrasting data can
be correlated to the different adopted protocol for drug loading.
In our previous work, the addition of IBU to already solubilised
CHP407 hydrogels led to only a partially effective loading of the
drug within micelle core, being a fraction of the polymer chains
already aggregated into micelles at the hydrogel preparation
temperature (i.e., 4◦C). Hence, a part of the added IBU probably
remained in the hydrophobic micelle inlets and was released
via diffusion mechanism. In contrast, in the present work the
addition of IBU during polymer solubilisation allowed its direct
incorporation into the micelles, which progressively assembled,
leading to an anomalous releasing mechanism characteristic of
drug delivery carriers with a double diffusive barrier (Boffito et al.,
2019b). Thus, working on the loading protocol, hydrophobic
drugs could be portioned among the different hydrophobic
domains present within the gels, i.e., micelle core and inlets, with
a consequent fine modulation of the release mechanism. CHP407
chain organisation into micelles upon temperature increase
could thus be successfully exploited to load high amounts
of hydrophobic molecules within the gels and avoid their
burst release. Other parameters potentially affecting the release
profile and mechanism are hydrogel composition, the initial
cargo concentration within the gels, and the releasing volume
surrounding them, which all together govern gel residence time
and the forces involved in the progressive delivery of the payload
from the systems to the surrounding watery environment.
This study has thus reported for the first time a thorough
investigation, at both the nano- and macro-scale, of the
interactions occurring between amphiphilic polymers and drugs
with different wettability, which in turn strongly influence
polymer chain arrangement in aqueous environment as well
as cargo localisation within the formed micelle network and
its release. All these aspects finally merge in the definition of
a new hydrogel platform with the huge potential of loading
high concentrations of drugs with different wettability and being
ad hoc customised to deliver selected payloads with a well-
defined time schedule.
CONCLUSION
In this work, an amphiphilic poly(ether urethane)-based hydrogel
was successfully developed, providing a step forward in the
design of versatile drug delivery systems. According to the
main goal of this investigation, IBU and IBUSS were selected
as model drugs showing different wettability. In addition, they
are widely employed in clinics as analgesic, anti-inflammatory,
and antipyretic agents. Their loading within a vehicle phase
opens the way to the possibility to locally release these drugs
in target area, with the additional advantage of avoiding
undesired side effects. The here-developed IBU- and IBUSS-
loaded systems could thus find widespread application in the
biomedical field in the treatment of many pathological states such
as chronic wounds and musculoskeletal and rheumatic disorders.
Our investigations evidenced that the characteristic PEU chain
organisation into micelles in response to temperature increase
could be exploited to encapsulate drugs with different wettability
with no detrimental alterations of the thermo-sensitivity (i.e.,
all the resulting formulations retained the capability to gel
in physiological conditions). In addition, the encapsulation of
hydrophobic molecules within the micelles ensured prolonged
drug release over time, thus avoiding their common burst release
from hydrophilic networks. Furthermore, the different drug
molecule arrangement within the gel network, as a consequence
of their hydrophilic/hydrophobic nature and loading protocol,
resulted in different drug releasing mechanism and timing. Thus,
the here-developed platform could also open the possibility to
design smart thermosensitive hydrogels able to simultaneously
encapsulate and release high amounts of different therapeutic
agents, thus eventually increasing the therapeutic efficacy through
their co-current delivery into a target tissue/organ.
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